Every metric below is drawn from Series A decks that closed in Q3 2025. The left column is where most pre-IND founders land. The right is where funded ones were.
Input four parameters. Get your percentile ranking against 200+ closed biotech Series A rounds. No email required for this step.
Aggregated benchmarks flatten the signal. These are stage-specific. A Phase I deck that performs like a preclinical deck loses the room in the first 10 minutes.
Interim safety data absent in 44% of passed decks
Safety profile absent in 71% of passed decks
MoA visualization missing in 83% of passed decks
No differentiated IP narrative — 91% of passed decks
Clinical path timeline absent in 62% of passed decks
Full benchmark dataset: 214 rounds × 47 variables × 6 stages
Including investor firm breakdowns, lead partner patterns, and slide-position heatmaps
Eye-tracking and time-on-slide data from 214 partner-level reviews. The gap between funded and passed decks is not where founders expect it.
Anon. Oncology Platform · IND Filed · Sep 2025
Anon. CNS Spinout · Preclinical · Sep 2025
Key finding: Both decks went to the same partner at the same firm in the same week. Deck A closed in 34 days. Deck B was passed after the first meeting. The difference was not the science — it was the structure of the argument.
Submit your deck for a full slide-level diagnostic. We run it against 214 closed rounds and return a ranked gap analysis with specific revision targets. 48-hour turnaround.
Not ready to share your deck? Get the full benchmark dataset by email.